Showing results (1161-1170 of 1,587) with videos related to

Sort By:
Pageof 159
JCO Oncology Practice|April 13, 2026
Phase II Trials in Radiation Oncology: When Success Fails to TranslateNina N Sanford, David J Sher
JCO Oncology Practice|August 19, 2026
Translating CRISPR to Practice in the Clinic: Transformative Therapy in Hemoglobinopathies and Emerging Applications in MalignanciesMiza Salim Hammoud, Rabi Hanna
JCO Oncology Practice|August 20, 2026
Improving Survival Among Adolescents and Young Adults With Cancer in the United States, 1975-2017: Long-Term Trends Across Age, Sex, and the HIV/AIDS EraIvan M Marrufo, Mackenzie J Ewart, Cody W Dorton, et al.
JCO Oncology Practice|September 22, 2026
Missed Precision: Gaps in Molecular Profiling Among Medicaid Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerTrisha Lal, Long Vu, Reine Abou Zeidane, et al.
JCO Oncology Practice|September 17, 2026
Oncology Care Model-Related Increases in Screening for Depression and Pain and Patient-Reported SymptomsTina Q Huang, Sean R McClellan, Gabriel A Brooks, et al.
JCO Oncology Practice|September 23, 2026
Financial Toxicity and Quality of Life After Bone Marrow Transplant: A Longitudinal, Prospective StudyS M Qasim Hussaini, Supriya Maheshwari, Luqin Deng, et al.
JCO Oncology Practice|September 23, 2026
Personalized Therapy in Advanced Cholangiocarcinoma: Contemporary Treatment Approaches and Future DirectionsFen Saj, Camila Braganca Xavier, Lipika Goyal, et al.
JCO Oncology Practice|September 21, 2026
Rural Cancer Care Delivery in the United States: A 2026 Update on Disparities, Vulnerable Populations, and Emerging ModelsWade Swenson, Zachary Schroeder
JCO Oncology Practice|October 1, 2026
Real-World Comparative Effectiveness of Abiraterone, Apalutamide, Enzalutamide, and Docetaxel Doublets for Metastatic Hormone-Sensitive Prostate CancerIfechukwu B Nwogu, Noemi Kreif, Hiba M Khan, et al.
JCO Oncology Practice|October 12, 2026
Participation of Patients With Gynecologic Cancer in Phase I Clinical Trials: Experience From Two National Cancer Institute-Designated Comprehensive Cancer CentersAnusha Adkoli, Charlotte Hadjadj, Krystle Vera, et al.
Pageof 159